PMID- 30245266 OWN - NLM STAT- MEDLINE DCOM- 20190501 LR - 20190501 IS - 1872-9142 (Electronic) IS - 0161-5890 (Linking) VI - 103 DP - 2018 Nov TI - Omentin-1 protects against bleomycin-induced acute lung injury. PG - 96-105 LID - S0161-5890(18)30773-9 [pii] LID - 10.1016/j.molimm.2018.09.007 [doi] AB - Acute lung injury (ALI) is characterized by inflammatory cell infiltration, macrophage activation, and excessive pro-inflammatory cytokine production. Bleomycin (BLM) is widely used to induce acute lung injury (ALI) and fibrosis in murine models. Intratracheally administration of BLM leads to the early stage of inflammatory response and the late stage of collagen deposition. Omentin-1 exerts an anti-inflammatory role in reducing tumor necrosis factor alpha (TNF-alpha)-induced cyclooxygenase-2 expression in endothelial cells and attenuating lipopolysaccharide (LPS)-induced ALI. However, the role of omentin-1 in BLM-induced ALI remains unclear. The aim of this study is to examine the effects of omentin-1 on BLM-induced ALI. We found that omentin-1 was decreased in lungs of BLM-induced ALI mice. Omentin-1 overexpression mediated by adenovirus alleviated lung injury and maintained the integrity of the alveolar septa. Omentin-1 overexpression also remarkably decreased the aggregation of neutrophil and macrophages activation, the expression of monocyte chemotactic protein 1 (MCP-1), and down-regulated expression of interleukin 1beta (IL-1beta) in lungs of BLM-induced ALI mice. Furthermore, we observed that omentin-1 reduced oxidative stress and suppressed the activation of NF-kappaB pathway in BLM-induced ALI and LPS-induced macrophages activation. Together, our findings indicated that omentin-1 protected mice from BLM-induced ALI may through reducing inflammatory cells recruitment and macrophages activation via alleviation of oxidative stress and NF-kappaB pathway. Thus, therapeutic strategies aiming to restore omentin-1 levels may be valuable for the prevention of BLM-induced ALI. CI - Copyright (c) 2018 Elsevier Ltd. All rights reserved. FAU - Zhou, Yan AU - Zhou Y AD - Department of Physiology, Xiangya School of Medicine, Central South University, Changsha, Hunan, China. FAU - Hao, CaiXia AU - Hao C AD - Department of Physiology, Xiangya School of Medicine, Central South University, Changsha, Hunan, China. FAU - Li, Chen AU - Li C AD - Department of Physiology, Changzhi medical college, Changzhi, Shanxi, China. FAU - Huang, XiaoTing AU - Huang X AD - Department of Physiology, Xiangya School of Medicine, Central South University, Changsha, Hunan, China. FAU - Li, XiaoHong AU - Li X AD - Department of Physiology, Xiangya School of Medicine, Central South University, Changsha, Hunan, China. FAU - Tang, YiTing AU - Tang Y AD - Department of Physiology, Xiangya School of Medicine, Central South University, Changsha, Hunan, China. FAU - Huang, YanHong AU - Huang Y AD - Department of Physiology, Xiangya School of Medicine, Central South University, Changsha, Hunan, China. FAU - Tang, SiYuan AU - Tang S AD - Xiangya School of Nursing, Central South University, Changsha, Hunan, China. FAU - Liu, Wei AU - Liu W AD - Xiangya School of Nursing, Central South University, Changsha, Hunan, China. FAU - Feng, DanDan AU - Feng D AD - Department of Physiology, Xiangya School of Medicine, Central South University, Changsha, Hunan, China. FAU - Xu, JianPing AU - Xu J AD - Department of Physiology, Xiangya School of Medicine, Central South University, Changsha, Hunan, China. FAU - Yue, ShaoJie AU - Yue S AD - Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Xie, Hui AU - Xie H AD - Movement System Injury and Repair Research Center, Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Luo, ZiQiang AU - Luo Z AD - Department of Physiology, Xiangya School of Medicine, Central South University, Changsha, Hunan, China. Electronic address: luoziqiang@csu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180921 PL - England TA - Mol Immunol JT - Molecular immunology JID - 7905289 RN - 0 (Cytokines) RN - 0 (GPI-Linked Proteins) RN - 0 (ITLN1 protein, human) RN - 0 (Inflammation Mediators) RN - 0 (Lectins) RN - 0 (Lipopolysaccharides) RN - 0 (NF-kappa B) RN - 0 (Protective Agents) RN - 11056-06-7 (Bleomycin) SB - IM MH - Acute Lung Injury/chemically induced/metabolism/*prevention & control MH - Animals MH - Bleomycin MH - Cells, Cultured MH - Cytokines/genetics/metabolism/*pharmacology MH - Female MH - GPI-Linked Proteins/genetics/metabolism/pharmacology MH - Inflammation Mediators/metabolism MH - Lectins/genetics/metabolism/*pharmacology MH - Lipopolysaccharides/pharmacology MH - Lung/*drug effects/metabolism/pathology MH - Macrophages, Peritoneal/*drug effects/metabolism MH - Mice, Inbred C57BL MH - NF-kappa B/metabolism MH - Protective Agents/pharmacology MH - Signal Transduction/drug effects OTO - NOTNLM OT - Acute lung injury OT - Bleomycin OT - Inflammation OT - NF-kappaB pathway OT - Omentin-1 OT - Oxidative stress EDAT- 2018/09/25 06:00 MHDA- 2019/05/02 06:00 CRDT- 2018/09/25 06:00 PHST- 2018/05/06 00:00 [received] PHST- 2018/09/05 00:00 [revised] PHST- 2018/09/09 00:00 [accepted] PHST- 2018/09/25 06:00 [pubmed] PHST- 2019/05/02 06:00 [medline] PHST- 2018/09/25 06:00 [entrez] AID - S0161-5890(18)30773-9 [pii] AID - 10.1016/j.molimm.2018.09.007 [doi] PST - ppublish SO - Mol Immunol. 2018 Nov;103:96-105. doi: 10.1016/j.molimm.2018.09.007. Epub 2018 Sep 21.